Biorce raised $52M in a Series A round announced on February 2, 2026. a TechBio company focused on transforming clinical trials through artificial intelligence.
a TechBio company focused on transforming clinical trials through artificial intelligence.
Biorce, based in Barcelona, Spain, announced $52M in Series A financing on February 2, 2026.
Participants include Norrsken VC, Mustard Seed Maze, Albert Nieto, YZR Capital, Nik Storonsky, Paulo Rosado, DST Global Partners, Arthur Mensch.
the company behind NEUROMARK, a minimally invasive solution to treat chronic rhinitis.
a platform that enables employees to build compliant enterprise software without writing code.
immunotherapy company with a proprietary platform technology applicable across a wide range of therapeutic areas.